Clinical Characteristics and Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma in East Asia

Jin Kyung Suh; Yi-Jin Gao; Jing-Yan Tang; Shiann-Tarng Jou; Dong-Tsamn Lin; Yoshiyuki Takahashi; Seiji Kojima; Ling Jin; Yonghong Zhang; Jong Jin Seo

doi:10.4143/crt.2019.219

Articles

Page Path: HOME > Cancer Res Treat > Volume 52(2); 2020 > Article

Original Article Clinical Characteristics and Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma in East Asia: Jin Kyung Suh, MD, PhD¹, Yi-Jin Gao, MD², Jing-Yan Tang, MD², Shiann-Tarng Jou, MD³, Dong-Tsamn Lin, MD³, Yoshiyuki Takahashi, MD⁴, Seiji Kojima, MD⁴, Ling Jin, MD⁵, Yonghong Zhang, MD^5,, Jong Jin Seo, MD, PhD^1,; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2020;52(2):359-368.
DOI: https://doi.org/10.4143/crt.2019.219
Published online: July 29, 2019

¹Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, Korea

²Department of Hematology/Oncology, Shanghai Children’s Medical Center, Shanghai, China

³Department of Pediatrics Hematology/Oncology, National Taiwan University Hospital, Taipei, Taiwan

⁴Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan

⁵Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, Beijing, China

Correspondence: Jong Jin Seo, MD, PhD Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
Tel: 82-2-3010-3383 Fax: 82-2-473-3725 E-mail: jjseo@amc.seoul.kr

Co-correspondence: Yonghong Zhang, MD Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, 56 Nan Lishi Road, Beijing 100045, China
Tel: 86-10-59617623 Fax: 86-13701251969 E-mail: yhzhang58@hotmail.com

*Jin Kyung Suh and Yi-Jin Gao contributed equally to this work.

• Received: April 22, 2019 • Accepted: July 26, 2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

9,123 Views
396 Download
3 Web of Science
2 Crossref
6 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
The presentations and geographic incidence of pediatric non-Hodgkin lymphoma (NHL) differ from those of adults. This study delineated the characteristics and outcomes of pediatric NHL in East Asia.
Materials and Methods
Medical records of 749 pediatric patients with NHL treated at participating institutions in mainland China, Japan, Korea, and Taiwan from January 2008 to December 2013 were reviewed. Demographic and clinical features, survival outcomes, and putative prognostic factors were analyzed.
Results
Five hundred thirty patients (71%) were male. The most common pathologic subtypes were Burkitt lymphoma (BL) (36%). Six hundred seven patients (81%) had advanced diseases at diagnosis. The 5-year overall survival and event-free survival (EFS) rates were 89% and 84%. The 5-year EFS rates of BL, lymphoblastic lymphoma, and diffuse large B-cell lymphoma were 88%, 88%, and 89%, and those of anaplastic large cell lymphoma (ALCL) and peripheral T-cell lymphoma (PTCL) were 71% and 56% (p < 0.001). Central nervous system involvement, high lactate dehydrogenase level (> 250 IU/mL), and advanced disease at diagnosis (≥ stage III) were associated with poor outcomes (p < 0.05). ALCL and PTCL relapsed more frequently than other pathologic subtypes (p < 0.001).
Conclusion
In East Asia, PTCL was more frequent than in Western countries, and bone marrow involvement did not affect treatment outcome. This international study should motivate future collaborative study on NHL in East Asia.
Key words: Lymphoma, Child, Treatment outcome, Retrospective studies

Introduction

Non-Hodgkin lymphoma (NHL) is a heterogeneous group of lymphoid malignancies and is the fourth most common malignancy in children and adolescents. Pediatric NHLs are known to have different distributions of pathologic subtypes and clinical features compared to adult NHLs. Most pediatric patients with NHL present diffuse high-grade lymphomas with frequent extranodal involvement [1,2]. Treatment outcomes of pediatric NHL have been improved with effective treatment strategies according to different pathologic subtypes, and the current overall survival (OS) rate exceeds 80% [3]. However, most of these findings on pediatric NHLs are derived from studies in Western countries. Multicenter investigations on Asian patients with pediatric NHL are lacking except for a few nationwide studies in Japan, China, and South Korea [4-6]. This might be attributed to the heterogeneity and the low incidence of pediatric NHL, which prevents large-scale clinical studies. Therefore, in this study we analyzed the demographic and clinical features of a large number of pediatric patients with NHL in Asian countries and compared them with those of previous reports on patients in Western countries to provide a basis for further clinical investigation.

Materials and Methods

The medical records of 769 pediatric patients with NHL, who were diagnosed and treated in four participating institutions of Beijing, Shanghai, Nagoya, and Seoul, and in centers in Taiwan between January 2008 and December 2013, were reviewed retrospectively. Participating centers were the Asan Medical Center Children’s Hospital (AMCCH) in Korea, Nagoya University Hospital (NUH) in Japan, Beijing Children’s Hospital (BCH) and Shanghai Children’s Medical Center in China, and Taiwan Pediatric Oncology Group centers. Demographic, clinical features, and survival outcomes were investigated.

NHL was diagnosed and classified according to the World Health Organization Classification of Hematological Malignancies [7]. Central review of the diagnosis was not performed. The St. Jude staging system was used for staging at diagnosis [8]. Staging analysis included physical examination, peripheral blood smear, and bone marrow (BM) aspiration and biopsy, cerebrospinal fluid (CSF) analysis, computed tomography (CT) and/or magnetic resonance imaging (MRI), fluorodeoxyglucose positron emission tomography and serum lactate dehydrogenase (LDH) concentration. Initial central nervous system (CNS) disease was diagnosed if one of the following was present: lymphoma cells in the CSF (> 5 cells/μL CSF in patients with lymphoblastic lymphoma [LL]), cerebral infiltrates on cranial CT or MRI, or cranial nerve palsy not caused by an extradural mass. Patients with blasts of ≥ 25% in BM were diagnosed with acute lymphoblastic lymphoma and were not included in this study. However, exclusively in patients with Burkitt lymphoma (BL), those with BM involvement were included as stage IV regardless of the percentage of blasts in the BM.

Patients were treated with multi-agent chemotherapy regimens according to participating institutions. Most of the regimens adopted the backbone of NHL-Berlin-Frankfurt-Munster (BFM) or Children’s Oncology Group (COG) protocols, which were stratified to the three main subgroups of LL, mature B-cell lymphoma, and anaplastic large cell lymphoma (ALCL).

Analysis of the probability of OS and event-free survival (EFS) was performed using the Kaplan-Meier method with differences compared by the log-rank test. The EFS was calculated from the date of diagnosis to the first event (first relapse, progression, secondary malignancy, or death from any cause) or the date of last follow-up. Cumulative incidence (CI) functions for competing events were constructed by the method of Kalbfleisch and Prentice and were compared with Gray’s test. CIs of relapse were estimated considering death without relapse and secondary malignancies as competing events. Differences in the distributions of different parameters were examined using the chi-square or Fisher exact test. Statistical analysis was conducted using SPSS software ver. 23.0 (IBM Corp., Armonk, NY) and R ver. 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria). p-values < 0.05 were considered statistically significant.

1. Ethical statement

This study was approved by the Institutional Review Board (IRB) of the Asan Medical Center Children’s Hospital (No. 2020-0284). Due to retrospective nature of this study, informed consent was waived by IRB. This study was performed in accordance with the recommendations of the Declaration of Helsinki for biomedical research involving human subjects.

Results

A total of 769 patients were enrolled in this study. Of them, 20 cases were excluded due to inadequate data. Patient characteristics are summarized in Table 1. Patients showed male predominance (male vs. female, 71% vs. 29%). The most common pathologic subtype was BL (36%) followed by LL (30%), ALCL (14%), and diffuse large B-cell lymphoma (DLBCL) (13%). Other rare lymphomas (2%) included seven other unspecified B-NHLs, five follicular lymphomas, three mucosa-associated lymphoid tissue lymphomas, two hydrovacciniforme-like lymphomas, and one plasmablastic lymphoma. There were slight differences in the pathologic subtype distributions according to the participating institutions and age. LL was more common in BCH, BL was more frequently observed in NUH, peripheral T-cell lymphoma (PTCL) was more often observed in AMCCH, and DLBCL was more common in Taiwan. In the analysis according to age, BL was predominant among patients under 14 years old while DLBCL was predominant among those aged 15-20 years (Fig. 1). Most patients (81%) had advanced disease (≥ stage III) at diagnosis. CNS involvement and BM involvement were observed in 63 (8%) and 217 (29%) patients, respectively. Anaplastic lymphoma kinase (ALK) status was available in 51 patients among 107 patients with ALCL status, and 40 patients (78%) of them showed ALK positivity. The differences in the patterns of BM involvement and disease extent at diagnosis, according to pathologic subtype, are shown in Table 2. BM involvement was more frequently observed in LL (48%) than in other subtypes, and patients with BL (83%), LL (93%), and ALCL (79%) were more frequently diagnosed with advanced diseases (p < 0.001). CNS involvement was more frequently observed in patients with BL (12%). However, the differences were not statistically significant (p > 0.05). Median age at diagnosis was 8 years (range, 1 to 19). Median LDH level at diagnosis was 500 IU/mL (range, 100 to 17,333). The pathologic subtypes included 268 BLs, 224 LLs, 97 DLBCLs, 107 ALCLs, 35 PTCLs, and 18 other rare lymphomas (others).

Of the 749 patients, 84 (11%) died. During the 50.5 months of median follow-up duration, the 5-year OS, EFS, and CI of relapse were 89%, 84%, and 13%,respectively (Fig. 2A). There were no significant differences in OS and EFS between institutions.

Univariate analysis of putative prognostic factors revealed that pathologic subtype, CNS involvement, stage, and initial LDH level were associated with prognosis (Table 3). Patients with PTCL showed significantly poorer prognosis, with 5-year EFS of 56%, compared with those with other subtypes (p < 0.05). CNS involvement at diagnosis was associated with poor survival outcome, while BM involvement was not. Patients with CNS involvement at diagnosis had lower 5-year OS and EFS than patients without CNS involvement (p < 0.05). Patients with early-stage NHL or those with LDH level below 250 IU/mL at diagnosis had excellent outcomes, with 5-year EFS of over 90%, compared to patients with advanced stage or high level of LDH (p < 0.05).

Ninety-one of the 749 patients (12%) experienced disease relapse. Median time to relapse from diagnosis was 8 months (range, 0 to 41 months). Along with the factors affecting prognosis, pathologic subtype, CNS involvement and stage were the factors affecting relapse. Patients with ALCL and PTCL experienced relapse more frequently than patients with other subtypes, and patients with CNS involvement and advanced stage also experienced relapses more frequently (Table 4).

Of the 91 patients who experienced relapse, 57 (63%) died, including the 16 patients who received no treatment after relapse. In the analysis of putative prognostic factors, relapse within 12 months from diagnosis, subtype of BL and LL, and salvage regimen without autologous hematopoietic stem cell transplantation (HSCT) were associated with poor outcomes in patients with relapse (Table 5). ALCL and PTCL showed a higher incidence of relapse (CI of relapse in ALCL and PTCL, 26%; CI of relapse in BL, LL, and DLBCL: 11%, 10%, and 7%, respectively), but these relapsed cases were salvaged successfully, while relapsed BL and LL showed more dismal outcomes with 5-year OS of 14% and 17%,respectively (Fig. 3). Regarding the salvage regimen, patients who received autologous HSCT had a successful outcome with 5-year OS of 77%.

Discussion

Through this multicenter study, we found that the demographic features and clinical characteristics of pediatric NHL in the East Asia were similar to those of Western countries. However, some distinct aspects were observed.

BL and LL were the most frequent pathologic subtypes followed by DLBCL or ALCL. A previous study analyzed 2,084 patients with pediatric NHL in Western countries and reported that the incidence of BL, LL, ALCL, DLBCL, and primary mediastinal large B-cell lymphoma were 48%, 21%, 10%, 8%, and 2%, respectively [9]. The pathologic subtype distribution showed different patterns according to the age of patients in western study: BL, LL, and ALCL were more commonly found in children aged under 15 years, while DLBCL, LL, and BL were more frequently found in patients aged 15 years and over [10]. Our study showed similar patterns of pathologic subtype distribution according to patient age as previous studies. In addition, rare pathologic subtypes of lymphoma accounted for 10% of cases in the 15-19-year-old age group compared to 3% in the 0-14-year-old age group. PTCL is a pathologic subtype of pediatric NHL, and a BFM study group reported that 38 of 4,083 pediatric patients (0.9%) with NHL were diagnosed with PTCL [11]. In our study, PTCL was more frequently found, in 35 (5%) of 749 patients. Earlier studies showed that in Asia, Epstein-Barr virus (EBV)-associated natural killer (NK)/T-cell lymphomas were more prevalent in adults than they were in Western countries [12,13]. However, there was no significant difference in the distribution of PTCL subtypes in children between the study of the BFM group and our study. In the BFM study, nine of the 38 patients (24%) with PTCL were reported to have NK/T-cell lymphomas, compared to 10 of the 35 patients (29%) with PTCL in our study. Thus, unlike previous studies on adult NHL, our study found no difference in the rate of NK/T-cell lymphoma. However, we cannot conclude that there are no ethnic or geographic differences in the biology of PTCL in children. Accordingly, further evaluation related to EBV infection is needed.

The clinical characteristics of pediatric NHL in our study were also similar to those of Western countries. The BFM group study on 2,084 pediatric patients with NHL reported a male to female ratio of 2.7:1 [9], similar to the value in our study (2.4:1). Seventy percent of pediatric patients with NHL were diagnosed with advanced diseases (≥ stage III) in the BFM study, compared to 81% in our study. While most patients were diagnosed with advanced diseases, BM involvement and CNS involvement were rarely observed. The BFM study observed 5% CNS involvement and 19% BM involvement, compared to 8% and 29%, respectively, in our study. Of note, BM and CNS involvement were more frequently observed in patients with BL and LL than in other subtypes.

Major advances in the treatment of pediatric NHL have been achieved over the last three decades. The current 3- or 5-year EFSs have been reported as approximately 70% to 90% in mature B-cell lymphomas, 75% to 85% in LLs, and 65% to 75% in ALCLs [1-3,14-18]. The development of efficacious treatment strategies for different pathologic subtypes might have resulted in the improved treatment outcomes of pediatric NHL. Our study found that contemporary treatment strategies were successful for treating pediatric patients with NHL in East Asian countries. The treatment outcomes of 749 patients enrolled in our study were comparable with those of Western countries: the 5-year OS and EFS were 89% and 84%, respectively. Even though treatment protocols differed between institutions, most of the protocols used were based on the backbone of the NHL-BFM or COG protocols. Patients were mostly treated with established protocols stratified to the three main subgroups: LL, mature B-cell lymphoma and ALCL. Therefore, the treatment strategies of each participating institutions were similar to each other. Of note, the treatment outcomes of each institution were not significantly different.

The analysis of prognostic factors in pediatric NHL has been mainly performed for each pathologic subtype in precedent studies. In mature B-cell NHL, advanced stage (≥ stage III), increased LDH at diagnosis, adolescent age, and CNS involvement have been observed as poor prognostic factors [19,20]. A recent BFM study on prognostic factors of mature B-cell NHL showed that presence of mediastinal involvement at the primary site was also a poor prognostic factor, while adolescent age was not associated with prognosis [21]. The COG group also found that disseminated disease, including BM and CNS, and a high LDH level were poor prognostic factors in mature B-cell NHL [22-24]. In LL, stage at diagnosis was the only identified risk factor, because the study of prognostic factors has been impeded by the rarity of the disease and by difficulties in obtaining appropriate material for immunophenotypic and molecular characterization [3,14]. In ALCL, mediastinal involvement, visceral involvement, or skin lesions were indicated as poor prognostic factors in the study of the European Intergroup for Childhood Non-Hodgkin Lymphoma [3,25]. Our study showed similar results: subtype of PTCL, CNS involvement, advanced stage, and high initial LDH level were associated with poor outcomes, whereas age, sex, and BM involvement were not associated with outcomes. A BFM study on pediatric NHL showed that age and sex had different effects on treatment outcomes and had different distributions according to the pathologic subtype [9]. As such, it may be more reasonable to perform analyses of prognostic factors independently for each subtype.

The outcomes of patients with relapse were dismal. The BFM group reported that 10% of 324 pediatric patients with LL experienced progression or relapse despite conventional frontline treatment, and the salvage rate was poor with an OS of 14% [26]. A Korean group study reported an OS of 32% in refractory or relapsed BL and mature B-ALL [27]. Similar results were noted in our study, showing a 5-year OS of 33% in relapsed cases. Of note, pathologic subtypes influenced the outcomes. Patients with BL and LL who had refractory or relapsed diseases had a higher rate of treatment failure with conventional salvage therapy than other subtypes: The 5-year OSs of relapsed BL and LL were 14% and 17%, respectively, while those of other subtypes were over 50%. These results show that conventional salvage regimens were not efficacious enough in most patients with relapsed BL and LL. Therefore, it is necessary to develop clinical studies to develop new salvage therapy for pediatric patients with relapsed NHLs, especially for BL and LL. Recent multicenter clinical trials of therapies for adult patients with refractory NHL and leukemia showed that blinatumomab and chimeric antigen receptor T-cell therapy could be efficacious salvage therapies [28-30]. This is a possible candidate for salvage therapy in pediatric patients with relapsed and refractory NHL.

As this is a case report form-based retrospective study that recruited a large number of cases from different countries, central review of pathological diagnosis was not possible, and the chemotherapy regimens used in each institution were not uniform. Even with these limitations, our study is noteworthy as the first report to reveal the demographic and clinical features of pediatric patients with NHL in East Asia. The results of this study could be a platform for future collaborative multinational studies in East Asia.

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

We appreciate TPOG members (especially Chao-Ping, Yang [P.I.]; Meng-Yao, Lu; Hsi-Che, Liu; Kang-hsi, Wu; Chih-Cheng, Hsiao; Jiann-Shiuh, Chen; Shyh-Shin, Chiou; Shih-Chung, Wang; Te-Kau, Chang; Tang-Her, Jaing; Shih-Hsiang, Chen [co-P.I.]; Yung-Li, Yang; Hsiu-Hao, Chang; Ting-Chi, Yeh; Ching-Tien, Peng; Pei-Chin, Lin; Yu-Mei, Liao; Ming-Tsan, Lin; Fang-Liang, Huang; Chao-Neng, Cheng; Jinn-Li, Wang; Wan-Ling, Ho) who contributed his/her patients in this study.

Fig. 1.

Pathologic subtype distribution according to age. BL was the most common subtype in patients under 14 years old (A), while DLBCL was in patients aged 15-20 years old (B). BL, Burkitt lymphoma; LL, lymphoblastic lymphoma; DLBCL, diffuse large B-cell lymphoma; ALCL, anaplastic large cell lymphoma; PTCL, peripheral T-cell lymphoma.

Fig. 2.

Treatment outcomes of the 749 pediatric patients with NHL (A) and treatment outcomes according to pathologic subtypes (B). OS, overall survival; EFS, event-free survival; CI, confidence interval; BL, Burkitt lymphoma; LL, lymphoblastic lymphoma; DLBCL, diffuse large B-cell lymphoma; ALCL, anaplastic large cell lymphoma; PTCL, peripheral T-cell lymphoma.

Fig. 3.

Treatment outcomes of patients with relapse according to subtype. Cumulative incidence of relapse (A) and overall survival (B) showed that, anaplastic large cell lymphoma (ALCL) and peripheral T-cell lymphoma (PTCL) had a higher incidence of relapse, but they were salvaged successfully compared to Burkitt lymphoma (BL) and lymphoblastic lymphoma (LL). DLBCL, diffuse large B-cell lymphoma.

Table 1.

Patients’ characteristics

Characteristic	No. (%) (n=749)
Age at diagnosis, median (range, yr)	7.5 (0.6-18.6)
Sex
Male	530 (71.0)
Female	219 (29.0)
Pathologic subtype
BL^a)	268 (35.7)
LL	224 (29.9)
DLBCL	97 (12.9)
ALCL	107 (14.3)
PTCL^b)	35 (4.6)
Others^c)	18 (2.4)
LDH level at diagnosis, median (range, IU/mL)	500 (100-9,587)
BM involvement (of the evaluable 748 patients)
Yes	217 (29.0)
No	531 (70.8)
CNS involvement
Yes	63 (8.4)
No	686 (91.6)
St. Jude stage
Ⅰ	28 (3.7)
Ⅱ	113 (15.1)
Ⅲ	368 (49.1)

BL, Burkitt lymphoma; LL, lymphoblastic lymphoma; DLBCL, diffuse large B-cell lymphoma; ALCL, anaplastic large cell lymphoma; PTCL, peripheral T-cell lymphoma; LDH, lactate dehydrogenase; BM, bone marrow; CNS, central nervous system.

^a) Burkitt leukemia was included in BL,

^b) PTCL-not otherwise specified, natural killer/T-cell lymphoma and subcutaneous panniculitis T-cell lymphoma were included in PTCL,

^c) Others: mucosa-associated lymphoid tissue lymphoma, other unspecified B-NHL, follicular lymphoma, hydrovascciniforme-like lymphoma, plasmablastic lymphoma.

Table 2.

BM, CNS involvement and disease extent at diagnosis according to pathologic subtype

	BL (n=268)	LL^a) (n=224)	ALCL (n=107)	DLBCL (n=97)	PTCL (n=35)	Others (n=18)	Total (n=749)	p-value
BM involvement
Yes	81 (30.2)	108 (48.2)	12 (11.2)	9 (9.3)	2 (5.7)	5 (27.7)	217 (28.9)	< 0.001
No	187 (69.8)	115 (51.3)	95 (88.8)	88 (90.7)	33 (94.2)	13 (72.2)	531 (70.9)
CNS involvement
Yes	32 (11.9)	17 (7.6)	5 (4.7)	8 (8.2)	1 (2.8)	0	63 (8.4)	0.087
No	236 (88.1)	207 (92.4)	102 (95.3)	89 (91.8)	34 (97.1)	18 (100)	686 (91.5)
Advanced disease (stage ≥ 3)
Yes	222 (82.8)	209 (93.3)	85 (79.4)	66 (68.0)	18 (51.4)	10 (55.5)	610 (81.4)	< 0.001
No	46 (17.2)	15 (6.7)	22 (20.6)	31 (32.0)	17 (48.5)	8 (44.4)	139 (18.5)

Values are presented as number (%). BM, bone marrow; CNS, central nervous system; BL, Burkitt lymphoma; LL, lymphoblastic lymphoma; ALCL, anaplastic large cell lymphoma; DLBCL, diffuse large B-cell lymphoma; PTCL, peripheral T-cell lymphoma.

^a) One patient with LL did not have data of initial BM.

Table 3.

Univariate analysis of putative prognostic factors

Factor	No.	5-Year OS (%)	p-value	5-Year EFS (%)	p-value
Sex
Male	530	89	0.678	84	0.651
Female	219	88		83
Age at diagnosis (yr)
≤ 14	681	88	0.383	84	0.289
> 14	68	92		80
Pathologic subtype
BL	268	89	0.032	88	< 0.001
LL	224	89		88
DLBCL	97	93		89
ALCL	107	84		71
PTCL	35	75		56
Others	18	88		80
BM involvement
Yes	217	86	0.479	81	0.482
No	531	89		85
CNS involvement
Yes	63	76	0.003	74	0.019
No	686	89		85
St. Jude stage
Ⅰ-Ⅱ	141	98	< 0.001	94	< 0.001
Ⅲ-Ⅳ	608	86		82
Initial LDH (IU/mL)
≤ 250	170	96	< 0.001	93	< 0.001
> 250	579	86		81

OS, overall survival; EFS, event-free survival; BL, Burkitt lymphoma; LL, lymphoblastic lymphoma; DLBCL, diffuse large B-cell lymphoma; ALCL, anaplastic large cell lymphoma; PTCL, peripheral T-cell lymphoma; BM, bone marrow; CNS, central nervous system; LDH, lactate dehydrogenase.

Table 4.

Characteristics of relapsed pediatric NHL

Characteristic	No. (n=749)	Non-relapse group (n=658)	Relapse group (n=91)	p-value
Time from diagnosis to relapse (mo)			7.8 (0-41.2)
Age at diagnosis (yr)		7 (1-18)	8.2 (0.6-16.4)	0.446
Sex (%)
Male	530	467 (71.0)	63 (69.2)	0.732
Female	219	191 (29.0)	28 (30.8)
Pathologic subtype
BL	268	239 (36.3)	29 (31.9)	0.001
LL	224	203 (30.9)	21 (23.1)
DLBCL	97	90 (13.7)	7 (7.7)
ALCL	107	81 (12.3)	26 (28.6)
PTCL	35	29 (4.4)	6 (6.6)
Others	18	16 (2.4)	2 (2.1)
LDH at diagnosis (IU/mL)		476 (100-9,587)	610 (113-17,333)	0.014
BM involvement
Yes	217	183 (27.8)	35 (38.4)	0.098
No	531	475 (72.2)	58 (63.7)
CNS involvement
Yes	63	50 (7.5)	13 (14.2)	0.031
No	686	608 (92.4)	78 (85.7)
St. Jude stage
Ⅰ	28	26 (4.0)	2 (2.2)	0.005
Ⅱ	113	108 (16.4)	5 (5.5)
Ⅲ	368	326 (49.5)	41 (45.1)
Ⅳ	240	197 (29.9)	43 (47.2)

Values are presented as median (range) or number (%). NHL, non-Hodgkin lymphoma; BL, Burkitt lymphoma; LL, lymphoblastic lymphoma; DLBCL, diffuse large B-cell lymphoma; ALCL, anaplastic large cell lymphoma; PTCL, peripheral T-cell lymphoma; LDH, lactate dehydrogenase; BM, bone marrow; CNS, central nervous system.

Table 5.

Univariate analysis of putative prognostic factors of relapsed pediatric NHL

Factor	No. (n=91)	5-Year OS (%)	p-value
Median time from diagnosis to relapse (mo)
≤ 12	68	30	0.003
> 12	23	46
Subtype
BL	29	14	0.001
LL	21	17
DLBCL	7	50
ALCL	26	51
PTCL	6	75
Others	2	67
Salvage regimen
CTx only	55	36	< 0.001
CTx+Auto-HSCT	10	77
CTx+Allo-HSCT	10	33

NHL, non-Hodgkin lymphoma; BL, Burkitt lymphoma; LL, lymphoblastic lymphoma; DLBCL, diffuse large B-cell lymphoma; ALCL, anaplastic large cell lymphoma; PTCL, peripheral T-cell lymphoma; CTx, chemotherapy; Auto-HSCT, autologous hematopoietic stem cell transplantation; allo-HSCT, allogeneic hematopoietic stem cell transplantation.

REFERENCES

1. Reiter A, Schrappe M, Parwaresch R, Henze G, Muller-Weihrich S, Sauter S, et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage: a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol. 1995;13:359–72. Article PubMed
2. Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999;94:3294–306. PubMed
3. Minard-Colin V, Brugieres L, Reiter A, Cairo MS, Gross TG, Woessmann W, et al. Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. J Clin Oncol. 2015;33:2963–74. Article PubMed PMC
4. Lymphoma Study Group, Subspecialty Group of Hematology, the Society of Pediatrics, Chinese Medical Association; Lymphoma Study Group Committee of Pediatrics Chinese Anti-Cancer Association. A collaborative study of children with lymphoblastic non-Hodgkin's lymphoma in China. Zhonghua Er Ke Za Zhi. 2015;53:931–7. PubMed
5. Mitsui T. Recent progress in the treatment of pediatric lymphoma in Japan. Rinsho Ketsueki. 2017;58:2168–77. PubMed
6. Hwang IG, Yoo KH, Lee SH, Park YH, Lim TK, Lee SC, et al. Clinicopathologic features and treatment outcomes in malignant lymphoma of pediatric and young adult patients in Korea: comparison of Korean all-ages group and Western younger age group. Clin Lymphoma Myeloma. 2007;7:580–6. Article PubMed
7. Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102:83–7. PubMed
8. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7:332–9. PubMed
9. Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005;131:39–49. Article PubMed
10. Hochberg J, Waxman IM, Kelly KM, Morris E, Cairo MS. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol. 2009;144:24–40. Article PubMed
11. Kontny U, Oschlies I, Woessmann W, Burkhardt B, Lisfeld J, Salzburg J, et al. Non-anaplastic peripheral T-cell lymphoma in children and adolescents: a retrospective analysis of the NHL-BFM study group. Br J Haematol. 2015;168:835–44. Article PubMed
12. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 1998;9:717–20. Article PubMed PDF
13. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30. Article PubMed
14. Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000;95:416–21. PubMed
15. Brugieres L, Deley MC, Pacquement H, Meguerian-Bedoyan Z, Terrier-Lacombe MJ, Robert A, et al. CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92:3591–8. PubMed
16. Cairo MS, Krailo MD, Morse M, Hutchinson RJ, Harris RE, Kjeldsberg CR, et al. Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. Leukemia. 2002;16:594–600. Article PubMed PDF
17. Williams DM, Hobson R, Imeson J, Gerrard M, McCarthy K, Pinkerton CR, et al. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on the United Kingdom Children's Cancer Study Group chemotherapy regimens. Br J Haematol. 2002;117:812–20. Article PubMed
18. Marky I, Bjork O, Forestier E, Jonsson OG, Perkkio M, Schmiegelow K, et al. Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology. J Pediatr Hematol Oncol. 2004;26:555–60. Article
19. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109:2736–43. Article PubMed PMC PDF
20. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773–80. Article PubMed PMC PDF
21. Cairo MS, Sposto R, Gerrard M, Auperin A, Goldman SC, Harrison L, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012;30:387–93. Article PubMed PMC
22. Mussolin L, Pillon M, d'Amore ES, Conter V, Piglione M, Lo Nigro L, et al. Minimal disseminated disease in high-risk Burkitt's lymphoma identifies patients with different prognosis. J Clin Oncol. 2011;29:1779–84. Article PubMed
23. Coustan-Smith E, Sandlund JT, Perkins SL, Chen H, Chang M, Abromowitch M, et al. Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children's oncology group. J Clin Oncol. 2009;27:3533–9. Article PubMed PMC
24. Shiramizu B, Goldman S, Kusao I, Agsalda M, Lynch J, Smith L, et al. Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report. Br J Haematol. 2011;153:758–63. Article PubMed PMC
25. Le Deley MC, Reiter A, Williams D, Delsol G, Oschlies I, McCarthy K, et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood. 2008;111:1560–6. Article PubMed PDF
26. Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. J Clin Oncol. 2009;27:3363–9. Article PubMed
27. Kim H, Park ES, Lee SH, Koo HH, Kim HS, Lyu CJ, et al. Clinical outcome of relapsed or refractory burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescents. Cancer Res Treat. 2014;46:358–65. Article PubMed PMC PDF
28. Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57–66. Article PubMed
29. Pishko A, Nasta SD. The role of novel immunotherapies in non-Hodgkin lymphoma. Transl Cancer Res. 2017;6:93–103. Article PubMed PMC
30. Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol. 2016;13:25–40. Article PubMed PDF

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Hemoglobinopathies, merozoite surface protein-2 gene polymorphisms, and acquisition of Epstein Barr virus among infants in Western Kenya
Perez K. Olewe, Shehu Shagari Awandu, Elly O. Munde, Samuel B. Anyona, Evans Raballah, Asito S. Amolo, Sidney Ogola, Erick Ndenga, Clinton O. Onyango, Rosemary Rochford, Douglas J. Perkins, Collins Ouma
BMC Cancer.2023;[Epub] CrossRef
iTRAQ-Based Proteomic Analysis Reveals Potential Serum Biomarkers for Pediatric Non-Hodgkin’s Lymphoma
Runhong Yu, Linna Cheng, Shiwei Yang, Yufeng Liu, Zunmin Zhu
Frontiers in Oncology.2022;[Epub] CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Clinical Characteristics and Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma in East Asia

Cancer Res Treat. 2020;52(2):359-368. Published online July 29, 2019

DOI: https://doi.org/10.4143/crt.2019.219

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
NOTES
REFERENCES

Clinical Characteristics and Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma in East Asia

Fig. 1. Pathologic subtype distribution according to age. BL was the most common subtype in patients under 14 years old (A), while DLBCL was in patients aged 15-20 years old (B). BL, Burkitt lymphoma; LL, lymphoblastic lymphoma; DLBCL, diffuse large B-cell lymphoma; ALCL, anaplastic large cell lymphoma; PTCL, peripheral T-cell lymphoma.

Fig. 2. Treatment outcomes of the 749 pediatric patients with NHL (A) and treatment outcomes according to pathologic subtypes (B). OS, overall survival; EFS, event-free survival; CI, confidence interval; BL, Burkitt lymphoma; LL, lymphoblastic lymphoma; DLBCL, diffuse large B-cell lymphoma; ALCL, anaplastic large cell lymphoma; PTCL, peripheral T-cell lymphoma.

Fig. 3. Treatment outcomes of patients with relapse according to subtype. Cumulative incidence of relapse (A) and overall survival (B) showed that, anaplastic large cell lymphoma (ALCL) and peripheral T-cell lymphoma (PTCL) had a higher incidence of relapse, but they were salvaged successfully compared to Burkitt lymphoma (BL) and lymphoblastic lymphoma (LL). DLBCL, diffuse large B-cell lymphoma.

Fig. 1.

Fig. 2.

Fig. 3.

Clinical Characteristics and Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma in East Asia

Characteristic	No. (%) (n=749)
Age at diagnosis, median (range, yr)	7.5 (0.6-18.6)
Sex
Male	530 (71.0)
Female	219 (29.0)
Pathologic subtype
BL^a)	268 (35.7)
LL	224 (29.9)
DLBCL	97 (12.9)
ALCL	107 (14.3)
PTCL^b)	35 (4.6)
Others^c)	18 (2.4)
LDH level at diagnosis, median (range, IU/mL)	500 (100-9,587)
BM involvement (of the evaluable 748 patients)
Yes	217 (29.0)
No	531 (70.8)
CNS involvement
Yes	63 (8.4)
No	686 (91.6)
St. Jude stage
Ⅰ	28 (3.7)
Ⅱ	113 (15.1)
Ⅲ	368 (49.1)

	BL (n=268)	LL^a) (n=224)	ALCL (n=107)	DLBCL (n=97)	PTCL (n=35)	Others (n=18)	Total (n=749)	p-value
BM involvement
Yes	81 (30.2)	108 (48.2)	12 (11.2)	9 (9.3)	2 (5.7)	5 (27.7)	217 (28.9)	< 0.001
No	187 (69.8)	115 (51.3)	95 (88.8)	88 (90.7)	33 (94.2)	13 (72.2)	531 (70.9)
CNS involvement
Yes	32 (11.9)	17 (7.6)	5 (4.7)	8 (8.2)	1 (2.8)	0	63 (8.4)	0.087
No	236 (88.1)	207 (92.4)	102 (95.3)	89 (91.8)	34 (97.1)	18 (100)	686 (91.5)
Advanced disease (stage ≥ 3)
Yes	222 (82.8)	209 (93.3)	85 (79.4)	66 (68.0)	18 (51.4)	10 (55.5)	610 (81.4)	< 0.001
No	46 (17.2)	15 (6.7)	22 (20.6)	31 (32.0)	17 (48.5)	8 (44.4)	139 (18.5)

Factor	No.	5-Year OS (%)	p-value	5-Year EFS (%)	p-value
Sex
Male	530	89	0.678	84	0.651
Female	219	88		83
Age at diagnosis (yr)
≤ 14	681	88	0.383	84	0.289
> 14	68	92		80
Pathologic subtype
BL	268	89	0.032	88	< 0.001
LL	224	89		88
DLBCL	97	93		89
ALCL	107	84		71
PTCL	35	75		56
Others	18	88		80
BM involvement
Yes	217	86	0.479	81	0.482
No	531	89		85
CNS involvement
Yes	63	76	0.003	74	0.019
No	686	89		85
St. Jude stage
Ⅰ-Ⅱ	141	98	< 0.001	94	< 0.001
Ⅲ-Ⅳ	608	86		82
Initial LDH (IU/mL)
≤ 250	170	96	< 0.001	93	< 0.001
> 250	579	86		81

Characteristic	No. (n=749)	Non-relapse group (n=658)	Relapse group (n=91)	p-value
Time from diagnosis to relapse (mo)			7.8 (0-41.2)
Age at diagnosis (yr)		7 (1-18)	8.2 (0.6-16.4)	0.446
Sex (%)
Male	530	467 (71.0)	63 (69.2)	0.732
Female	219	191 (29.0)	28 (30.8)
Pathologic subtype
BL	268	239 (36.3)	29 (31.9)	0.001
LL	224	203 (30.9)	21 (23.1)
DLBCL	97	90 (13.7)	7 (7.7)
ALCL	107	81 (12.3)	26 (28.6)
PTCL	35	29 (4.4)	6 (6.6)
Others	18	16 (2.4)	2 (2.1)
LDH at diagnosis (IU/mL)		476 (100-9,587)	610 (113-17,333)	0.014
BM involvement
Yes	217	183 (27.8)	35 (38.4)	0.098
No	531	475 (72.2)	58 (63.7)
CNS involvement
Yes	63	50 (7.5)	13 (14.2)	0.031
No	686	608 (92.4)	78 (85.7)
St. Jude stage
Ⅰ	28	26 (4.0)	2 (2.2)	0.005
Ⅱ	113	108 (16.4)	5 (5.5)
Ⅲ	368	326 (49.5)	41 (45.1)
Ⅳ	240	197 (29.9)	43 (47.2)

Factor	No. (n=91)	5-Year OS (%)	p-value
Median time from diagnosis to relapse (mo)
≤ 12	68	30	0.003
> 12	23	46
Subtype
BL	29	14	0.001
LL	21	17
DLBCL	7	50
ALCL	26	51
PTCL	6	75
Others	2	67
Salvage regimen
CTx only	55	36	< 0.001
CTx+Auto-HSCT	10	77
CTx+Allo-HSCT	10	33

Table 1. Patients’ characteristics

Burkitt leukemia was included in BL,

PTCL-not otherwise specified, natural killer/T-cell lymphoma and subcutaneous panniculitis T-cell lymphoma were included in PTCL,

Others: mucosa-associated lymphoid tissue lymphoma, other unspecified B-NHL, follicular lymphoma, hydrovascciniforme-like lymphoma, plasmablastic lymphoma.

Table 2. BM, CNS involvement and disease extent at diagnosis according to pathologic subtype

One patient with LL did not have data of initial BM.

Table 3. Univariate analysis of putative prognostic factors

Table 4. Characteristics of relapsed pediatric NHL

Table 5. Univariate analysis of putative prognostic factors of relapsed pediatric NHL